Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Proteasome inhibitors (e.g., bortezomib, carfilzomib) are effective in hematologic cancers but not solid tumors.
• Liposarcomas (LPS) represent a significant unmet need in solid cancer therapy.

Purpose of the Study:

• To investigate the efficacy of proteasome inhibition in liposarcomas.
• To identify synergistic drug combinations with carfilzomib for LPS treatment.
• To elucidate the molecular mechanisms underlying carfilzomib's action and combination therapies in LPS.

Main Methods:

• Quantitative nuclear protein profiling and phospho-kinase arrays to identify mechanisms of action.
• Global protein level analysis to identify key regulatory enzymes.
• High-throughput drug screening to discover novel combination therapies.
• In vitro and in vivo efficacy studies of carfilzomib combinations.

Main Results:

• Liposarcomas demonstrate susceptibility to proteasome inhibition.
• Selinexor (XPO1 inhibitor) and SC26196 (FADS2 inhibitor) synergize with carfilzomib.
• Combination therapies interfere with ribosome biogenesis and inhibit PRAS40.
• FADS2, a fatty acid synthesis enzyme, is downregulated by proteasome inhibition.
• Cyclosporin A enhances carfilzomib efficacy in vitro and in vivo.

Conclusions:

• Carfilzomib and its novel combinations show therapeutic potential for liposarcomas.
• Targeting FADS2 and leveraging synergistic drug interactions offer new avenues for LPS treatment.
• These findings support the repurposing of carfilzomib and its combinations for clinical management of LPS.